AtriCure

Careers at AtriCure

• AdministrationOperations
• Clinical & Regulatory Affairs
• Compliance
• Customer Service
• Finance
• Human Resources
• Information Technology
  
• Legal
• Manufacturing
• Marketing
• Operations
• Professional Education
• Quality Assurance
• Research and Development
• Sales 

2010

The AtriClip LAA Exclusion System was cleared by FDA for the occlusion of the left atrial appendage, under direct visualization, in conjunction with other open cardiac surgical procedures.

The first patient was enrolled in AtriCure’s DEEP AF feasibility study. The study evaluated the safety and effectiveness of a dual epicardial and endocardial ablation procedure for patients presenting with persistent atrial fibrillation or longstanding persistent atrial fibrillation.

2011

Following successful completion of the ABLATE study, AtriCure’s Isolator Synergy ablation system became the first device approved by FDA for the treatment of persistent or longstanding persistent atrial fibrillation.

2012

AtriCure partnered with Dr. James L. Cox and launched the Maze IV training program in the United States to educate healthcare providers on the safe and effective use of the AtriCure Isolator Synergy System in the treatment of non-paroxysmal forms of atrial fibrillation.

2013

AtriCure expanded the Maze IV training program to Europe.

2014

A milestone was reached as AtriCure surpassed 150,000 ablations and over 200,000 patients treated. The Minneapolis office was also opened.

AtriCure acquired Endoscopic Technologies, Inc. (Estech), which expanded AtriCure's product portfolio with the addition of the Fusion Surgical Ablation System and a comprehensive suite of cardiac surgery instruments. As a result, AtriCure opened the San Ramon office.

2015

Launched the availability of its cryoICE cryo ablation probe (CRYO2) to provide cryoanalgesia for temporary pain management. AtriCure’s cryoICE is the first FDA cleared cryo ablation probe for the treatment of cardiac arrhythmias and for the temporary ablation of peripheral nerves to block pain.

A milestone in LAA management is reached with more than 50,000 patients worldwide having been treated with AtriClip LAA Exclusion System.

AtriCure acquired nContact Surgical, LLC.

On November 3, 2015, the Cincinnati headquarters opened its newly built facility in Mason, Ohio.

AtriCure announces first patient enrolled in international Afib clinical study, Combined Endoscopic Epicardial and Percutaneous Endocardial Ablation versus Repeated Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation (CEASE-AF).

2016

First patient enrolled in ATLAS clinical study. This observational study explores the use of the AtriClip device to decrease complications associated with Post-Operative Afib (POAF) by targeting specific cardiac surgery patient populations at the highest risk of developing POAF.

The cryoFORM cryoablation probe was made commercially available in the U.S. This probe offers increased probe flexibility to adapt to a variety of surgical ablation procedures.

A new AtriClip device, called the AtriClip PRO2 was made commercially available in the U.S and European markets. This new device has increased functionality that enhances the capability of occluding the left atrial appendage in minimally-invasive cardiac surgeries.

Gained approval for the AtriClip products and cryoICE platform in Japan.

First patient enrolled in the FROST trial. This clinical study examines the cryoICE Cryoablation Probe, CRYO2, for pain management in post thoracic procedures via intercostal cryoanalgesia.

STS 2017 Clinical Practice Guidelines for Surgical Treatment of Afib changed surgical ablation at the time of structural heart surgery from a Class II to a Class I recommendation. The recommendations have gone from it is “reasonable” to do an ablation in Afib patients undergoing major types of structural heart surgery to it is “recommended” to do an ablation.

2017

A milestone was reached as AtriCure surpassed 100,000 AtriClip LAA Exclusion System devices sold worldwide.

The AtriClip PRO•V Device has been made commercially available in the U.S. The new device offers several modifications which enable easier navigation and placement when operating in minimally-invasive surgery (MIS) environments.